SciClone Pharmaceuticals (Holdings) Ltd
HKEX:6600
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Revenue
Forecast
Revenue Estimate
SciClone Pharmaceuticals (Holdings) Ltd
For the last 5 years the compound annual growth rate for SciClone Pharmaceuticals (Holdings) Ltd's revenue is 18%. The projected CAGR for the next 2 years is 16%.
Operating Income
Forecast
Operating Income Estimate
SciClone Pharmaceuticals (Holdings) Ltd
For the last 5 years the compound annual growth rate for SciClone Pharmaceuticals (Holdings) Ltd's operating income is 19%. The projected CAGR for the next 2 years is 7%.
Net Income
Forecast
Net Income Estimate
SciClone Pharmaceuticals (Holdings) Ltd
For the last 5 years the compound annual growth rate for SciClone Pharmaceuticals (Holdings) Ltd's net income is 16%. The projected CAGR for the next 2 years is 9%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is SciClone Pharmaceuticals (Holdings) Ltd's stock price target?
Not Available
SciClone Pharmaceuticals (Holdings) Ltd doesn't have any price targets made by Wall Street professionals.
What is SciClone Pharmaceuticals (Holdings) Ltd's Revenue forecast?
Projected CAGR
16%
For the last 5 years the compound annual growth rate for SciClone Pharmaceuticals (Holdings) Ltd's revenue is 18%. The projected CAGR for the next 2 years is 16%.
What is SciClone Pharmaceuticals (Holdings) Ltd's Operating Income forecast?
Projected CAGR
7%
For the last 5 years the compound annual growth rate for SciClone Pharmaceuticals (Holdings) Ltd's operating income is 19%. The projected CAGR for the next 2 years is 7%.
What is SciClone Pharmaceuticals (Holdings) Ltd's Net Income forecast?
Projected CAGR
9%
For the last 5 years the compound annual growth rate for SciClone Pharmaceuticals (Holdings) Ltd's net income is 16%. The projected CAGR for the next 2 years is 9%.
